Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
Nona Biosciences appointed Dr. Hongjiang Miao as Chief AI Officer to lead its AI-driven drug discovery efforts and advance the company's A³ Strategy.
Dr. Miao will be based in Shanghai and report directly to Dr. Di Hong, CEO of Nona Biosciences.
Nona Biosciences is a global biotechnology company providing integrated solutions for biological drug discovery and development from 'Idea to IND' (I to I®).
The appointment aims to strengthen Nona's use of cutting-edge AI technologies in its drug discovery platform to accelerate innovation and expand global cooperation.
Nona Biosciences integrates multiple advanced platforms including Harbour Mice® technology, AI-driven drug discovery, single-B cell screening, and modalities for next-generation antibody therapeutics.
Dr. Di Hong, appointed CEO in October 2025, leads the company's strategic growth with an emphasis on technology innovation and AI integration, under which Dr. Miao's role is critical.